{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:05:04Z","timestamp":1770073504540,"version":"3.49.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0112530","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T20:20:16Z","timestamp":1417551616000},"page":"e112530","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma"],"prefix":"10.1371","volume":"9","author":[{"given":"Songlin","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoliu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,12,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/S1590-8658(10)60507-5","article-title":"The changing pattern of epidemiology in hepatocellular carcinoma","volume":"42","author":"H Nordenstedt","year":"2010","journal-title":"Dig Liver Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"JM Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"A Forner","year":"2012","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"JM Llovet","year":"2003","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"SM Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"S Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"L Adnane","year":"2006","journal-title":"Methods Enzymol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"F Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"J Bruix","year":"2012","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial","volume":"48","author":"AL Cheng","year":"2012","journal-title":"Eur J Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary","volume":"17","author":"AR Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"LL Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref14","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"N Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"CB Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"JF Tierney","year":"2007","journal-title":"Trials"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1365-2036.2011.04823.x","article-title":"Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"34","author":"M Pinter","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"M Iavarone","year":"2011","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12013-012-9353-2","article-title":"Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma","volume":"63","author":"Y Yang","year":"2012","journal-title":"Cell Biochem Biophys"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12032-012-0345-2","article-title":"Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions","volume":"30","author":"PR Brunocilla","year":"2013","journal-title":"Med Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/08923973.2011.617373","article-title":"Sorafenib in hepatocellular carcinoma - a post marketing evaluation","volume":"34","author":"MP Trojniak","year":"2012","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/MEG.0b013e32834bd2d0","article-title":"A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors","volume":"23","author":"T Song","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000313701","article-title":"A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma","volume":"78","author":"SM Balsom","year":"2010","journal-title":"Oncology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","article-title":"Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response","volume":"115","author":"T Yau","year":"2009","journal-title":"Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"GK Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00280-009-1226-z","article-title":"Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study","volume":"66","author":"SD Prete","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"M Kudo","year":"2011","journal-title":"Eur J Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"AL Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"GK Abou-Alfa","year":"2010","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"JM Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"PJ Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12032-013-0655-z","article-title":"Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma","volume":"30","author":"O Abdel-Rahman","year":"2013","journal-title":"Med Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S1499-3872(12)60209-4","article-title":"Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review","volume":"11","author":"X Zhang","year":"2012","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.7314\/APJCP.2013.14.2.691","article-title":"Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma","volume":"14","author":"Z Wang","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"G Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials","volume":"29","author":"JM Llovet","year":"1999","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hep.510280322","article-title":"A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators","volume":"28","year":"1998","journal-title":"Hepatology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"JM Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1548-5315(11)70751-3","article-title":"Managing the side effects of sorafenib and sunitinib","volume":"3","author":"LS Wood","year":"2006","journal-title":"Community Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jhep.2004.09.006","article-title":"Angiogenesis and hepatocellular carcinoma","volume":"41","author":"D Semela","year":"2004","journal-title":"J Hepatol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0112530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T15:51:54Z","timestamp":1589039514000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0112530"}},"subtitle":[],"editor":[{"given":"Yitao","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,2]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0112530","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,2]]}}}